Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | PRKCG | P05129 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | LYN | P07948 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31134966 | 0.80 | KMT2A (0.53) | MEN1MAPK10GFERKMT2AALDH1A1 | |
| SCHEMBL692480 | 0.80 | KMT2A (0.53) | MEN1MAPK10GFERKMT2AALDH1A1 | |
| SCHEMBL1272593 | 0.79 | — | — | |
| SCHEMBL28506082 | 0.78 | — | — | |
| SCHEMBL15124961 | 0.77 | PRKCD (0.50) | MAPK10CHEK1IKBKBAURKANPC1 | |
| SCHEMBL18901342 | 0.73 | AURKA (0.69) | MEN1KMT2AALDH1A1CHEK1IKBKB | |
| SCHEMBL834683 | 0.72 | MAPT (0.50) | MEN1GFERKMT2AALDH1A1GAA | |
| SCHEMBL165738 | 0.72 | ROCK1 (0.45) | MEN1KMT2ACDK1CDK2 | |
| SCHEMBL21925753 | 0.72 | — | — | |
| SCHEMBL3435500 | 0.71 | HPGD (0.49) | ALDH1A1GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115819405-A | Pyrimidinylaminopyrazole derivatives and their use as leucine-rich repeat kinase 2 inhibitors | 沪渝人工智能研究院 | 2023-03-21 | — | — | CN | claimed |
| US-20260116889-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2026-04-30 | — | — | US | disclosed |
| CN-118878521-B | Preparation method of LRRK2 inhibitor | 苏州美诺医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118878521-A | Preparation method of LRRK2 inhibitor | 苏州美诺医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4450505-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | Whan In Pharmaceutical Co., Ltd. (KR) | 2024-10-23 | — | — | EP | disclosed |
| EP-3717473-B1 | POLYMORPHS AND SOLID FORMS OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF PRODUCTION | DENALI THERAPEUTICS INC (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3975719-A4 | MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT | Denali Therapeutics Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023113510-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | 환인제약 주식회사 | 2023-06-22 | — | — | WO | disclosed |
| CN-115894456-A | Deuterated pyrazole aminopyrimidine compound, pharmaceutical composition and application | 药康众拓(江苏)医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115819405-A | Pyrimidinylaminopyrazole derivatives and their use as leucine-rich repeat kinase 2 inhibitors | 沪渝人工智能研究院 | 2023-03-21 | — | — | CN | disclosed |
| US-9382230-B2 | Methods and compositions for modulating Ire1, SRC and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015090496-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-01-08 | — | — | US | disclosed |
| US-8815885-B2 | Methods and compositions for modulating IRE1, SRC, and ABL activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8114989-B2 | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2012-02-14 | — | — | US | disclosed |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2340248-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | The Regents of the University of California (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010031056-A2 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| CN-101238116-A | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011575-A1 | METHODS AND COMPOSITIONS FOR MODULATING IRE1, SRC, AND ABL ACTIVITY | XBP1, SRC, HSP90B1 | ACHE 3914/4885PLAU 1589/4885MEN1 4777/4885 |
| US-20260116889-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE CONTAINING SAME AS ACTIVE INGREDIENT | PARK7, LRRK2, SNCA | ACHE 183/4885PLAU 3971/4885MEN1 3335/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | ACHE 4875/4885PLAU 2682/4885MEN1 2604/4885 |
| US-20110319436-A1 | Methods and Compositions for Modulating IRE1, SRC, and ABL Activity | XBP1, SRC, HSP90B1 | ACHE 3914/4885PLAU 1589/4885MEN1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.